Clinical Trials Browser

Active not recruiting × Interventional × ipatasertib × Clear all

NCT05172258 2026-03-18

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT04931342 2026-03-10

BOUQUET

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT05276973 2025-12-19

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

Phase 1 Active not recruiting

25 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03959891 2025-09-29

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

Phase 1 Active not recruiting

Breast Neoplasms

NCT03385655 2025-08-21

Prostate Cancer Biomarker Enrichment and Treatment Selection

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03673787 2025-05-14

IceCAP

Phase 1/2 Active not recruiting

Glioblastoma

NCT05498896 2025-03-10

BARBICAN

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms